{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T06:52:21Z","timestamp":1746600741449,"version":"3.37.3"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T00:00:00Z","timestamp":1567123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0221958","type":"journal-article","created":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T17:24:35Z","timestamp":1567185875000},"page":"e0221958","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Association of virological breakthrough and clinical outcomes in entecavir-treated HBeAg-positive chronic hepatitis B"],"prefix":"10.1371","volume":"14","author":[{"given":"Yi-Jie","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Shun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Zen","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Sen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8993-3039","authenticated-orcid":true,"given":"Yen-Chun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,8,30]]},"reference":[{"issue":"10003","key":"pone.0221958.ref001","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"A Schweitzer","year":"2015","journal-title":"Lancet (London, England)"},{"issue":"3","key":"pone.0221958.ref002","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4254\/wjh.v4.i3.74","article-title":"Hepatitis B: Epidemiology and prevention in developing countries","volume":"4","author":"E Franco","year":"2012","journal-title":"World Journal of Hepatology"},{"issue":"2","key":"pone.0221958.ref003","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.canlet.2013.08.035","article-title":"Hepatitis B virus-induced hepatocellular carcinoma","volume":"345","author":"C Xu","year":"2014","journal-title":"Cancer Lett"},{"issue":"2","key":"pone.0221958.ref004","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1055\/s-2006-939752","article-title":"Hepatitis B virus-related cirrhosis: natural history and treatment","volume":"26","author":"CM Chu","year":"2006","journal-title":"Semin Liver Dis"},{"issue":"1","key":"pone.0221958.ref005","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/hep.26110","article-title":"Causes of death in patients with hepatitis B: a natural history cohort study in the United States","volume":"58","author":"JL Szpakowski","year":"2013","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"1","key":"pone.0221958.ref006","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"NA Terrault","year":"2016","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"3","key":"pone.0221958.ref007","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load","volume":"130","author":"UH Iloeje","year":"2006","journal-title":"Gastroenterology"},{"issue":"2","key":"pone.0221958.ref008","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1365-2893.2009.01168.x","article-title":"Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa","volume":"17","author":"ME Mendy","year":"2010","journal-title":"Journal of viral hepatitis"},{"issue":"1","key":"pone.0221958.ref009","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"CJ Chen","year":"2006","journal-title":"Jama"},{"issue":"3","key":"pone.0221958.ref010","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s12072-009-9140-3","article-title":"HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B","volume":"3","author":"Y-F Liaw","year":"2009","journal-title":"Hepatology international"},{"issue":"2","key":"pone.0221958.ref011","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"Journal of hepatology"},{"issue":"1","key":"pone.0221958.ref012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"SK Sarin","year":"2016","journal-title":"Hepatology international"},{"issue":"5","key":"pone.0221958.ref013","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1053\/j.gastro.2010.01.042","article-title":"Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death","volume":"138","author":"JD Chen","year":"2010","journal-title":"Gastroenterology"},{"issue":"4","key":"pone.0221958.ref014","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jhep.2012.11.039","article-title":"Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside\/nucleotide analogue therapy: finite treatment duration unlikely","volume":"58","author":"S Chevaliez","year":"2013","journal-title":"Journal of hepatology"},{"issue":"1","key":"pone.0221958.ref015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1365-2893.2009.01146.x","article-title":"Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B","volume":"17","author":"RG Gish","year":"2010","journal-title":"Journal of viral hepatitis"},{"issue":"12","key":"pone.0221958.ref016","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1093\/jac\/dkr388","article-title":"Nucleoside\/nucleotide analogues in the treatment of chronic hepatitis B","volume":"66","author":"J Fung","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"pone.0221958.ref017","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy","volume":"49","author":"DJ Tenney","year":"2009","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"7","key":"pone.0221958.ref018","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/ajg.2011.45","article-title":"Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety","volume":"106","author":"MF Yuen","year":"2011","journal-title":"The American journal of gastroenterology"},{"issue":"3","key":"pone.0221958.ref019","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: An update","volume":"53","author":"J Bruix","year":"2011","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"7","key":"pone.0221958.ref020","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1053\/j.gastro.2007.04.061","article-title":"Hepatocellular carcinoma: epidemiology and molecular carcinogenesis","volume":"132","author":"HB El-Serag","year":"2007","journal-title":"Gastroenterology"},{"issue":"2","key":"pone.0221958.ref021","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","article-title":"2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B","volume":"136","author":"YF Liaw","year":"2009","journal-title":"Gastroenterology"},{"issue":"12","key":"pone.0221958.ref022","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1111\/jgh.12283","article-title":"Differential roles of serum hepatitis B virus DNA and hepatitis B surface antigen level in predicting virological breakthrough in patients receiving lamivudine therapy","volume":"28","author":"CW Su","year":"2013","journal-title":"Journal of gastroenterology and hepatology"},{"issue":"4","key":"pone.0221958.ref023","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/s10620-010-1537-2","article-title":"The level of HBV DNA at month 12 is an important predictor of virological breakthrough during adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance","volume":"56","author":"MC Kim","year":"2011","journal-title":"Digestive diseases and sciences"},{"issue":"4 Pt 1","key":"pone.0221958.ref024","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1053\/jhep.2001.27563","article-title":"Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy","volume":"34","author":"MF Yuen","year":"2001","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"1","key":"pone.0221958.ref025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jhep.2008.12.019","article-title":"Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B","volume":"51","author":"S Zeuzem","year":"2009","journal-title":"Journal of hepatology"},{"issue":"4","key":"pone.0221958.ref026","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jfma.2013.10.023","article-title":"HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients","volume":"114","author":"CY Peng","year":"2015","journal-title":"J Formos Med Assoc"},{"key":"pone.0221958.ref027","article-title":"On-treatment HBV DNA level could predict HBeAg seroclearance in patients with HBeAg-positive chronic hepatitis B with entecavir therapy","author":"YJ Huang","year":"2017","journal-title":"J Chin Med Assoc"},{"issue":"6","key":"pone.0221958.ref028","doi-asserted-by":"crossref","first-page":"647","DOI":"10.7150\/ijms.5904","article-title":"Efficacy of Lamivudine or Entecavir against Virological Rebound after Achieving HBV DNA Negativity in Chronic Hepatitis B Patients","volume":"10","author":"T Miyauchi","year":"2013","journal-title":"International Journal of Medical Sciences"},{"issue":"6","key":"pone.0221958.ref029","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/S1499-3872(14)60303-9","article-title":"Partial virological response to three different nucleotide analogues in naive patients with chronic hepatitis B","volume":"13","author":"EG Yegin","year":"2014","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"4","key":"pone.0221958.ref030","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/jmv.21681","article-title":"Clinical and virological effects of long-term (over 5 years) lamivudine therapy","volume":"82","author":"Y Hashimoto","year":"2010","journal-title":"Journal of medical virology"},{"journal-title":"Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment","year":"2016","author":"JH Kim","key":"pone.0221958.ref031"},{"issue":"8","key":"pone.0221958.ref032","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/ajg.2014.145","article-title":"Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis","volume":"109","author":"SS Kim","year":"2014","journal-title":"The American journal of gastroenterology"},{"issue":"1","key":"pone.0221958.ref033","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jhep.2010.02.026","article-title":"Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease","volume":"53","author":"JR Eun","year":"2010","journal-title":"Journal of hepatology"},{"issue":"5","key":"pone.0221958.ref034","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1872-034X.2011.00785.x","article-title":"Long-term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine","volume":"41","author":"H Kobashi","year":"2011","journal-title":"Hepatology research: the official journal of the Japan Society of Hepatology"},{"issue":"6","key":"pone.0221958.ref035","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1002\/hep.24318","article-title":"Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice","volume":"53","author":"C Hongthanakorn","year":"2011","journal-title":"Hepatology (Baltimore, Md)"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0221958","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T04:00:28Z","timestamp":1588996828000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0221958"}},"subtitle":[],"editor":[{"given":"Chen-Hua","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,8,30]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0221958","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2019,8,30]]}}}